The European Survey on Adverse Systemic Reactions in Allergen Immunotherapy (EASSI): A paediatric assessment

Pediatric Allergy and Immunology

Volumn 28, Issue 1, 2017, Pages 60-70

  Rodríguez del Río, Pablo ^a   Vidal, Carmen ^b   Just, Jocelyne ^c   Tabar, Ana I ^d   Sanchez Machin, Inmaculada ^e   Eberle, Peter ^f   Borja, Jesus ^g   Bubel, Petra ^h   Pfaar, Oliver ^i,j   Demoly, Pascal ^k   Calderón, Moises A ^l  

^a HOSPITAL INFANTIL UNIVERSITARIO NIÑO JESÚS   (Spain)

^b HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^c ARMAND TROUSSEAU HOSPITAL   (France)

^d Instituto de Investigación Sanitaria de Navarra   (Spain)

^e Hospital de Ofra   (Spain)

^f Private Office   (Germany)

^g Hospital General Universitario   (Spain)

^h Ear Nose and Throat Surgery   (Germany)

ⁱ Centre for Rhinology and Allergology   (Germany)

^j UNIVERSITY OF HEIDELBERG   (Germany)

^k HÔPITAL ARNAUD DE VILLENEUVE   (France)

^l NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

more..

Author keywords

adrenaline; allergen immunotherapy; anaphylaxis; children; Medical Dictionary for Regulatory Activities; risk factor; subcutaneous; sublingual; systemic reaction

Indexed keywords

ALLERGEN; EPINEPHRINE; GRASS POLLEN EXTRACT; HOUSE DUST ALLERGEN;

ADULT; ALLERGEN IMMUNOTHERAPY; ALTERNARIA; ANAPHYLAXIS; ARTICLE; ASTHMA; DANDER; FEMALE; FOLLOW UP; GRASS POLLEN; HEALTH SURVEY; HUMAN; IMMUNOTHERAPY; MAJOR CLINICAL STUDY; MALE; MITE; PRIORITY JOURNAL; RHINITIS; SENSITIZATION; SKIN MANIFESTATION; SUBLINGUAL IMMUNOTHERAPY; TABLET; TREE; WEED; ADOLESCENT; ALLERGIC RHINITIS; CHILD; DESENSITIZATION; DRUG SURVEILLANCE PROGRAM; EUROPE; IMMUNOLOGY; POLLEN; PREVALENCE; PROCEDURES; PROSPECTIVE STUDY; QUESTIONNAIRE; RASH; RISK FACTOR;

ADOLESCENT; ADULT; ADVERSE DRUG REACTION REPORTING SYSTEMS; ANAPHYLAXIS; ANTIGENS, DERMATOPHAGOIDES; ASTHMA; CHILD; DESENSITIZATION, IMMUNOLOGIC; EUROPE; EXANTHEMA; FOLLOW-UP STUDIES; HUMANS; POLLEN; PREVALENCE; PROSPECTIVE STUDIES; RHINITIS, ALLERGIC; RISK FACTORS; SURVEYS AND QUESTIONNAIRES;

EID: 85010646471     PISSN: 09056157     EISSN: 13993038     Source Type: Journal    
DOI: 10.1111/pai.12660     Document Type: Article

References (41)

1. Jutel M, Agache I, Bonini S, et al. International consensus on allergy immunotherapy. J Allergy Clin Immunol 2015: 136: 556–68.
2. Global Initiative for Asthma [Internet]. Global Initiative for Asthma - GINA. [cited 2016 Aug 18]. Available from: http://ginasthma.org/
3. Caminati M, Dama AR, Djuric I, et al. Incidence and risk factors for subcutaneous immunotherapy anaphylaxis: the optimization of safety. Expert Rev Clin Immunol 2015: 11: 233–45.
4. Calderon MA, Alves B, Jacobson M, Hurwitz B, Sheikh A, Durham S. Allergen injection immunotherapy for seasonal allergic rhinitis. Cochrane Database Syst Rev 2007: (1): CD001936.
5. Erekosima N, Suarez-Cuervo C, Ramanathan M, et al. Effectiveness of subcutaneous immunotherapy for allergic rhinoconjunctivitis and asthma: a systematic review. Laryngoscope 2014: 124: 616–27.
6. Calderón MA, Rodríguez Del Río P, Vidal C, et al. An EAACI ‘European Survey on Adverse Systemic Reactions in Allergen Immunotherapy (EASSI)’: the methodology. Clin Transl Allergy 2014: 4: 22.
7. Calderón MA, Vidal C, Rodríguez del Río P, et al. European Survey on Adverse Systemic Reactions in Allergen Immunotherapy (EASSI): a real life clinical assessment. Clin Transl Allergy 2014: 4: 22
8. MedDRA [Internet]. [cited 2015 Dec 24]. Available from: http://www.meddra.org/
9. WHO | Adolescent Health [Internet]. WHO. [cited 2016 Apr 18]. Available from: http://www.who.int/topics/adolescent_health/en/
10. Contopoulos-Ioannidis DG, Seto I, Hamm MP, et al. Empirical evaluation of age groups and age-subgroup analyses in pediatric randomized trials and pediatric meta-analyses. Pediatrics 2012: 129(Suppl 3): S161–84.
11. Wahn U, Klimek L, Ploszczuk A, et al. High-dose sublingual immunotherapy with single-dose aqueous grass pollen extract in children is effective and safe: a double-blind, placebo-controlled study. J Allergy Clin Immunol 2012: 130: 886–93.
12. Ibañez MD, Kaiser F, Knecht R, et al. Safety of specific sublingual immunotherapy with SQ standardized grass allergen tablets in children. Pediatr Allergy Immunol 2007: 18: 516–22.
13. Williams K, Thomson D, Seto I, et al. Standard 6: age groups for pediatric trials. Pediatrics 2012: 129(Suppl 3): S153–60.
14. Barnetson RSC, Rogers M. Childhood atopic eczema. BMJ 2002: 324: 1376–9.
15. Calderon MA, Gerth van Wijk R, Eichler I, et al. Perspectives on allergen-specific immunotherapy in childhood: an EAACI position statement. Pediatr Allergy Immunol 2012: 23: 300–6.
16. Eng PA, Reinhold M, Gnehm HPE. Long-term efficacy of preseasonal grass pollen immunotherapy in children. Allergy 2002: 57: 306–12.
17. Marogna M, Spadolini I, Massolo A, Canonica GW, Passalacqua G. Randomized controlled open study of sublingual immunotherapy for respiratory allergy in real-life: clinical efficacy and more. Allergy 2004: 59: 1205–10.
18. Jacobsen L, Niggemann B, Dreborg S, et al. Specific immunotherapy has long-term preventive effect of seasonal and perennial asthma: 10-year follow-up on the PAT study. Allergy 2007: 62: 943–8.
19. Novembre E, Galli E, Landi F, et al. Coseasonal sublingual immunotherapy reduces the development of asthma in children with allergic rhinoconjunctivitis. J Allergy Clin Immunol 2004: 114: 851–7.
20. Morjaria JB, Caruso M, Rosalia E, Russo C, Polosa R. Preventing progression of allergic rhinitis to asthma. Curr Allergy Asthma Rep 2014: 14: 412.
21. Guideline on the clinical development of products for specific immunotherapy for the treatment of allergic diseases. - WC500003605.pdf [Internet]. [cited 2016 Mar 21]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003605.pdf
22. Nelson MR, Petersen MM, Wolverton WO, Mikita CP. Allergen immunotherapy extract treatment set preparation: making a safer and higher quality product for patients. Curr Allergy Asthma Rep 2013: 13: 399–405.
23. Calderón MA, Cox L, Casale TB, Moingeon P, Demoly P. Multiple-allergen and single-allergen immunotherapy strategies in polysensitized patients: looking at the published evidence. J Allergy Clin Immunol 2012: 129: 929–34.
24. Tabar AI, González Delgado P, Sánchez Hernández C, Basagaña Torrento M, Moreno Benítez F, Arina M. Phase II/III clinical trial to assess the tolerability and immunological effect of a new updosing phase of Dermatophagoides mix-based immunotherapy. J Investig Allergol Clin Immunol 2015: 25 : 40–6.
25. Pfaar O, Jung K, Wolf H, et al. Immunological effects and tolerability of a new fast updosed immunologically enhanced subcutaneous immunotherapy formulation with optimized allergen/adjuvant ratio. Allergy 2012: 67: 630–7.
26. Pfaar O, Sager A, Robinson DS. Safety and effect on reported symptoms of depigmented polymerized allergen immunotherapy: a retrospective study of 2927 paediatric patients. Pediatr Allergy Immunol 2015: 26: 280–6.
27. Cox L, Larenas-Linnemann D, Lockey RF, Passalacqua G. Speaking the same language: the World Allergy Organization Subcutaneous Immunotherapy Systemic Reaction Grading System. J Allergy Clin Immunol 2010: 125: 569–74, 574.e1–574.e7.
28. Calderón MA, Simons FER, Malling H-J, Lockey RF, Moingeon P, Demoly P. Sublingual allergen immunotherapy: mode of action and its relationship with the safety profile. Allergy 2012: 67: 302–11.
29. Canonica GW, Cox L, Pawankar R, et al. Sublingual immunotherapy: World Allergy Organization position paper 2013 update. World Allergy Organ 2014: 7: 6.
30. Migueres M, Fontaine J-F, Haddad T, et al. Characteristics of patients with respiratory allergy in France and factors influencing immunotherapy prescription: a prospective observational study (REALIS). Int J Immunopathol Pharmacol 2011: 24: 387–400.
31. CSM Update: desensitising vaccines. Br Med J (Clin Res Ed) 1986: 293: 948.
32. Reid MJ, Lockey RF, Turkeltaub PC, Platts-Mills TA. Survey of fatalities from skin testing and immunotherapy 1985–1989. J Allergy Clin Immunol 1993: 92: 6–15.
33. Schiappoli M, Ridolo E, Senna G, et al. A prospective Italian survey on the safety of subcutaneous immunotherapy for respiratory allergy. Clin Exp Allergy 2009: 39: 1569–74.
34. Dondi A, Tripodi S, Panetta V, et al. Pollen-induced allergic rhinitis in 1360 Italian children: comorbidities and determinants of severity. Pediatr Allergy Immunol 2013: 24: 742–51.
35. Moreno C, Cuesta-Herranz J, Fernández-Távora L, Alvarez-Cuesta EImmunotherapy Committee, Sociedad Española de Alergología e Inmunología Clínica. Immunotherapy safety: a prospective multi-centric monitoring study of biologically standardized therapeutic vaccines for allergic diseases. Clin Exp Allergy 2004: 34: 527–31.
36. Bernstein DI, Wanner M, Borish L, Liss GM, Immunotherapy Committee, American Academy of Allergy, Asthma and Immunology. Twelve-year survey of fatal reactions to allergen injections and skin testing: 1990–2001. J Allergy Clin Immunol 2004: 113: 1129–36.
37. Justicia JL, Barasona MJ, Serrano P, Moreno C, Guerra F. Predicting patients at high-risk of systemic reactions to cluster allergen immunotherapy: a pilot prospective observational study. J Investig Allergol Clin Immunol 2007: 17: 386–92.
38. Illi S, von Mutius E, Lau S, et al. Perennial allergen sensitisation early in life and chronic asthma in children: a birth cohort study. Lancet 2006: 368: 763–70.
39. Casanovas M, Sastre J, Fernández-Nieto M, Lluch M, Carnés J, Fernández-Caldas E. Double-blind study of tolerability and antibody production of unmodified and chemically modified allergen vaccines of Phleum pratense. Clin Exp Allergy 2005: 35: 1377–83.
40. Alvarez-Cuesta E, Bousquet J, Canonica GW, et al. Standards for practical allergen-specific immunotherapy. Allergy 2006: 61(Suppl 82): 1–20.
41. Fitzhugh DJ, Bernstein DI. Should epinephrine autoinjectors be prescribed to all patients on subcutaneous immunotherapy? J Allergy Clin Immunol Pract 2016: 4: 862–67.